On 28 October 2010, India’s Central Drugs Standard Control Organization (CDSCO) released new guidance for industry for submission of new drug applications (NDAs) in the common technical document (CTD) format.
India regulatory authority to adopt CTD format for NDAs
Home/Guidelines | Posted 11/02/2011 0 Post your comment
The CTD has already been developed for Japan, the EU and the US through the International Conference on Harmonisation (ICH) process.
Up until now, applicants in India have used many different approaches in organising the information for NDAs and the differences in organisation of data in each application has made reviewing difficult and has often resulted in the omission of critical data or analyses, in turn leading to unnecessary delays in approval.
By adopting the CTD format the CDSCO hopes to improve approval times for the importation, manufacture and marketing of new drugs. In addition, this should also simplify the exchange of regulatory information between India and other regulatory authorities.
The guidance document is available for comment for 60 days on the website of the CDSCO.
Source: CDSCO
Policies & Legislation
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
New FDA guidance on statistical approaches to establishing bioequivalence
Comments (0)
Post your comment